Mollie Sitkowski Speaks With Endpoints on Impacts of Tariffs on the Pharma Industry

Government and regulatory partner Mollie Sitkowski shared the impacts that new tariffs might have on the pharma industry in an article for Endpoints.

The publication reported that President Donald Trump’s recently announced broad 10% global tariffs is a move that pharma industry groups worry will upend drug costs and manufacturing. Sitkowski said that the tariffs, in addition to the mass firings sweeping across the FDA, are a “double whammy” for the pharma industry. “If you’re trying to move manufacturing to a more friendly country and trying to get the FDA to authorize that, it’s going to take longer,” she said.

“Having all drug products from every country hit with tariffs is a major blow to everyone, and it’s going to increase costs,” Sitkowski said regarding the European impact.

The full article is available to Endpoints subscribers.